Introduction
============

Coronary artery disease (CAD) is the principal individual cause of mortality and morbidity worldwide. A recent report on the Global Burden of Disease, which proposes disability-adjusted life years (DALYs, calculated as the sum of years of life lost and years lived with disability) as a new metric to measure disease burden, indicates that CAD accounted for the largest proportion of DALYs due to a single cause worldwide in 2010, explaining 5% of the total number of DALYS ([Figure 1](#f1-tacg-7-015){ref-type="fig"}).[@b1-tacg-7-015]

CAD is a complex chronic inflammatory disease, characterized by remodeling and narrowing of the coronary arteries supplying oxygen to the heart. It can have various clinical manifestations, including stable angina, acute coronary syndrome, and sudden cardiac death. It has a complex etiopathogenesis and a multifactorial origin related to environmental factors, such as diet, smoking, and physical activity, and genetic factors[@b2-tacg-7-015] that modulate risk of the disease both individually and through interaction.

In this narrative review, we summarize the main etiopathogenic mechanisms that underlie CAD, with a focus on current knowledge concerning the genetic architecture of the disease and the clinical utility of this knowledge.

Atherosclerosis, the main etiopathogenic mechanism of CAD
=========================================================

Atherosclerosis is the main etiopathogenic process that causes CAD, and its progression is related to an interplay between environmental and genetic factors, with the latter exerting their effects either directly or via cardiovascular risk factors ([Figure 2](#f2-tacg-7-015){ref-type="fig"}). Although clinical ischemic cardiovascular events usually appear after the fifth decade of life in men and the sixth decade of life in women, this process starts early in life, even during fetal development.[@b3-tacg-7-015]

Briefly, atherosclerosis is a silent progressive chronic process characterized by accumulation of lipids, fibrous elements, and inflammatory molecules in the walls of the large arteries.[@b4-tacg-7-015]--[@b8-tacg-7-015] This process begins with the efflux of low-density lipoprotein (LDL) cholesterol to the subendothelial space, which can then be modified and oxidized by various agents. Oxidized/modified LDL particles are potent chemotactic molecules that induce expression of vascular cell adhesion molecule and intercellular adhesion molecule at the endothelial surface, and promote monocyte adhesion and migration to the subendothelial space. Monocytes differentiate to macrophages in the intima media. Recently, different subsets of monocytes have been identified, and their roles appear to be different according to the phase of atherosclerosis in which they are involved.[@b9-tacg-7-015] Macrophages bind oxidized LDL via scavenger receptors to become foam cells,[@b5-tacg-7-015] and also have proinflammatory functions, including the release of cytokines such as interleukins and tumor necrosis factor. The final result of this process is formation of the first typical atherosclerotic lesion, ie, the fatty streak, in which foam cells are present in the subendothelial space.

Other types of leukocytes, such as lymphocytes and mast cells, also accumulate in the subendothelial space.[@b10-tacg-7-015] The cross-talk between monocytes, macrophages, foam cells, and T-cells results in cellular and humoral immune responses, and ultimately in a chronic inflammatory state with the production of several proinflammatory molecules.[@b11-tacg-7-015],[@b12-tacg-7-015] This process continues with the migration of smooth muscle cells from the medial layer of the artery into the intima, resulting in the transition from a fatty streak to a more complex lesion.[@b5-tacg-7-015] Once smooth muscle cells are in the intima media, they produce extracellular matrix molecules, creating a fibrous cap that covers the original fatty streak. Foam cells inside the fibrous cap die and release lipids that accumulate in the extracellular space, forming a lipid-rich pool known as the necrotic core.[@b13-tacg-7-015] The result of this process is formation of the second atherosclerotic lesion, the fibrous plaque.

The thickness of the fibrous cap is key for maintaining the integrity of the atherosclerotic plaque,[@b8-tacg-7-015] and two types of plaque can be defined depending on the balance between formation and degradation of this fibrous cap, ie, stable and unstable or vulnerable. Stable plaques have an intact, thick fibrous cap composed of smooth muscle cells in a matrix rich in type I and III collagen.[@b14-tacg-7-015] Protrusion of this type of plaque into the lumen of the artery produces flow-limiting stenosis, leading to tissue ischemia and usually stable angina. Vulnerable plaques have a thin fibrous cap made mostly of type I collagen and few or no smooth muscle cells, but abundant macrophages and proinflammatory and prothrombotic molecules.[@b8-tacg-7-015],[@b10-tacg-7-015] These plaques are prone to erosion or rupture, exposing the core of the plaque to circulating coagulation proteins, causing thrombosis, sudden occlusion of the artery lumen,[@b8-tacg-7-015],[@b10-tacg-7-015] and usually an acute coronary syndrome. Intraplaque hemorrhage is also a potential contributor to progression of atherosclerosis, and appears to occur when the vasa vasorum invades the intima from the adventitia.[@b15-tacg-7-015]

Study of the genetic architecture of disease
============================================

In order to study the genetic factors associated with a disease, several sequential steps must be followed. The first step involves quantification of the genetic component of the disease, which can be expressed as its heritability, ie, the proportion of the total population variance of the phenotype at a particular time or age that is attributable to genetic variation.[@b16-tacg-7-015] The heritability of some phenotypes associated with arteriosclerosis has already been determined, and generally ranges from 40% to 55% ([Table 1](#t1-tacg-7-015){ref-type="table"}).[@b17-tacg-7-015],[@b18-tacg-7-015]

The second step is to study the genetic architecture of the disease, ie, identify the loci, and within these loci, the genetic variants that modulate disease susceptibility. However, this task is one of the greatest challenges in current genetic research. Depending on the observed patterns of inheritance, it is possible to classify genetic diseases in two broad classes, ie, monogenic or Mendelian diseases, in which genetic variation in one gene accounts for most or all of the variation in disease risk;[@b19-tacg-7-015] and complex diseases, which are characterized by complex patterns of inheritance caused by the combination of multiple genetic variants (often with a small effect) and environmental factors, and modulated by their mutual interaction.[@b20-tacg-7-015] For example, in the case of CAD, the effects of known genetic variants range from an odds ratio of 1.04 to approximately 1.30 per copy of the risk allele.[@b21-tacg-7-015] Studies of the genetic architecture of a disease generally have two approaches, ie, linkage and association studies.[@b17-tacg-7-015]

Linkage studies
---------------

In these studies, large families with several affected and unaffected relatives across one or more generations are identified and recruited.[@b22-tacg-7-015],[@b23-tacg-7-015] Classically, large numbers of genetic markers, uniformly distributed throughout the genome, are analyzed to see if their transmission from generation to generation is associated with the presence of the disease (segregation). The initial objective is to identify regions of the genome that contain genes predisposing to or causing the disease under study. Thereafter, the chromosomal region that segregates with the disease can be fine-mapped to identify the causal gene.[@b17-tacg-7-015],[@b22-tacg-7-015],[@b23-tacg-7-015] This type of study has been successful in identifying many disease genes, particularly those that cause Mendelian traits, but less successful in identifying genes associated with complex diseases.[@b24-tacg-7-015] In the case of CAD, notable successes include the identification of variants in *ALOX5AP* as being associated with coronary and cerebrovascular diseases,[@b25-tacg-7-015] in *MEF2A* as being associated with CAD,[@b26-tacg-7-015] and in *PCSK9* as a gene for which variation is relevant in the metabolism of cholesterol.[@b27-tacg-7-015]

Association studies
-------------------

Association studies are likely to be more effective tools than linkage studies for studying genetically complex traits because they can have greater statistical power to detect genetic variants with small effects.[@b28-tacg-7-015] These types of studies evaluate the association between genetic variants (usually single nucleotide polymorphisms or copy number variations) and the presence/absence of a disease or a specific phenotype. The biggest challenges for this type of study are the accuracy of phenotype definition and replication of the findings. In order to identify genetic variants with small effects, large sample sizes are required, which are usually obtained by pooling different samples and populations, potentially with different phenotyping methods or criteria. In many cases, this heterogeneity results in dilution of the effects of causal genetic variants. In other cases, the phenotype itself may be difficult to define (eg, fibromyalgia) or show substantial intraindividual variability (eg, blood pressure), diluting the observable effect of the causal variant on the phenotype of interest. There are several types of association studies, as follows.

### Candidate gene studies

Association studies in candidate genes, usually known to be related to intermediate traits, have been widely used for the study of complex diseases.[@b4-tacg-7-015],[@b29-tacg-7-015],[@b30-tacg-7-015] This approach is based on an a priori hypothesis generated from knowledge of the disease pathogenesis or previous results.[@b17-tacg-7-015],[@b31-tacg-7-015] In the 1990s, this type of research became very popular and many studies analyzing the relationship between genetic variants and phenotypes were published, although their main findings were often difficult to replicate.[@b32-tacg-7-015]

### Genome-wide association studies

The goal of genome-wide association studies (GWAS) is to identify genetic variants associated with complex phenotypes without the need for prior selection of candidate loci or genes.[@b33-tacg-7-015] GWAS are based on two assumptions: first, a large proportion of common variation in the genome can be captured by a relatively small number of genetic variants, an hypothesis that is supported by evidence from the HapMap project;[@b34-tacg-7-015] and, second, common complex diseases are mainly caused by common genetic variants.

This type of study became possible through technologic advances that allowed large numbers of single nucleotide polymorphisms to be genotyped throughout the genome and common patterns of linkage disequilibrium in different populations to be determined, thanks to studies like the Human Genome Project and the HapMap Project.[@b34-tacg-7-015],[@b35-tacg-7-015] This evidence allowed the possibility of searching the human genome for common variants associated with a huge variety of phenotypes and diseases.[@b36-tacg-7-015] Moreover, powerful association analysis methods and software have also been developed.[@b37-tacg-7-015],[@b38-tacg-7-015] These studies are hypothesis-free, and due to the multiple comparisons and the need to reduce the burden of potential type I errors, they have to correct the *P*-value to be considered statistically significant according to the number of tests performed. Usually, this statistical significance threshold is located at a *P*-value, 10^−8^.

In parallel, international collaborations and consortia have provided new insights in medical research.[@b39-tacg-7-015] While the number of studies that use this methodology has increased rapidly in recent years ([Figure 3](#f3-tacg-7-015){ref-type="fig"}), this type of design is known to have some limitations ([Table 2](#t2-tacg-7-015){ref-type="table"}). These include the low proportion of heritability explained by the genetic variants identified, which has been found to be lower than 10% for most phenotypes,[@b4-tacg-7-015],[@b40-tacg-7-015] and the fact that the results are based on statistical association and do not provide functional insights. However, these studies have consistently identified hundreds of loci in dozens of clinically important phenotypes,[@b4-tacg-7-015],[@b41-tacg-7-015] providing further insights into the genetics of complex diseases.

### Whole-genome sequencing studies

The human genome contains approximately 3.1 billion nucleotides with approximately 56 million genetic variants. The exome, ie, the part of the genome formed by protein-coding exons, comprises approximately 30 million nucleotides and 23,500 genes.[@b42-tacg-7-015] Rapidly improving whole-genome sequencing (WGS) technologies are creating new research avenues based on sequencing entire individuals,[@b39-tacg-7-015],[@b42-tacg-7-015] and the rapidly decreasing costs of WGS will soon allow this technology to be used for tackling the genetic architecture of disease.[@b43-tacg-7-015] WGS are expected to contribute to better definition of the genetic basis of a range of phenotypes, responses to therapy, and clinical outcomes. Although WGS mainly focus on Mendelian disorders, the WGS approach is becoming important for identifying and analyzing rare variants, which might have larger effects on disease risk than the common variants identified by GWAS.[@b42-tacg-7-015]

One of the main disadvantages of WGS is the rate of false positive/false negative results in variant calling, and identification of the true causal genetic variant. Considering a false positive rate of 2%, an analysis of three billion genetic variants per genome would yield 60,000,000 miscalled variants. Therefore, false positives are expected to remain a major limitation of WGS, and alternative methods for validating variants identified by this approach will be necessary. Also, WGS will have a real challenge in identifying the true causal genetic variants among all alleles because all genes and proteins carry several nonpathogenic variants. For this reason, a classification of genetic variants according to the strength of the evidence for causality has been proposed as follows: disease-causing, likely disease-causing, disease-associated, functional but not associated with disease; and unknown biological function.[@b42-tacg-7-015]

Current knowledge of genetic architecture of CAD
================================================

Our understanding of the genetic architecture of CAD has improved considerably since 2007 when the first GWAS of this disease were published. The first two studies were published simultaneously and identified the 9p21 locus to be associated with myocardial infarction[@b44-tacg-7-015] and CAD,[@b45-tacg-7-015] and a third study replicated these findings.[@b46-tacg-7-015] At the beginning of 2013, a meta-analysis of several GWAS identified a final set of about 40 genetic variants associated with CAD ([Table 3](#t3-tacg-7-015){ref-type="table"}) that explains approximately 6% of the heritability of CAD.[@b21-tacg-7-015] Some of these variants are related to lipid metabolism, blood pressure, and inflammation, which confirms the importance of these pathways in the pathogenesis of CAD.[@b21-tacg-7-015] In contrast, this study found no overlap between these CAD loci and those associated with type 2 diabetes or glucometabolic traits. Moreover, most of these CAD loci are located in intergenic regions, or in regions with unknown function or where the relationship to atherosclerosis or its intermediate traits is unknown.

Genetics of cardiovascular risk factors
---------------------------------------

Classical cardiovascular risk factors, such as hypertension, diabetes, dyslipidemia, and obesity, are also considered to be complex traits caused by the interplay between genetic and environmental factors, as in the case of CAD. The GWAS approach has had a similar degree of success in identifying the genetic architecture of these risk factors and that of CAD, in that only a small fraction of the heritability of these phenotypes has been explained ([Table 4](#t4-tacg-7-015){ref-type="table"}).[@b47-tacg-7-015]--[@b53-tacg-7-015] While some of these genetic variants are also associated with CAD risk, others are not, ie, they have such small effects that very sample sizes would be required to detect them.

Clinical utility of genetic knowledge
=====================================

The identification of genetic variants associated with disease has allowed us to improve our understanding of its pathogenesis, and ultimately to reduce the burden of disease at both the individual and population levels. Information derived from genetic studies could potentially help to reduce the burden of disease in three main ways, ie, the identification of new pharmacologic targets, improvements in identification of high-risk individuals, and pharmacogenomics.

Identification of new pharmacologic targets
-------------------------------------------

Genetic studies can shed light on new metabolic pathways associated with the development and progression of atherosclerosis, and provide clues for identifying new pharmacologic targets. The following two examples illustrate the promise as well as the potential difficulties of this field.

### PCSK9

A clear example of the success of genetic studies in identifying molecules that may become new therapeutic targets is the *PCSK9* gene. This gene was initially discovered by linkage studies to be associated with autosomal dominant hypercholesterolemia,[@b27-tacg-7-015] for which new causal mutations were identified in 2003.[@b54-tacg-7-015] The PCSK9 protein is crucial for metabolism of LDL cholesterol through its role in degradation of the LDL receptor, such that inhibition of this protein could become a viable treatment for hypercholesterolemia.[@b55-tacg-7-015] Recent clinical trials in patients with primary hypercholesterolemia have shown that combination treatment with REGN727/SAR236553, a human monoclonal antibody to PCSK9, and either 10 mg or 80 mg of atorvastatin resulted in significantly greater reduction of LDL cholesterol than that obtained by 80 mg of atorvastatin alone.[@b56-tacg-7-015]

### 9p21 region

The genetic variants associated with CAD at the 9p21 locus, which has been the top hit in all CAD GWAS since 2007, lie in an intergenic region close to a cluster of cell-cycle regulating tumor suppressor genes (*CDKN2A* and *CDKN2B*) that overlap with a nonprotein coding RNA (*CDKN2BAS* or *ANRIL*). While various hypotheses have been proposed to explain the functional basis of this association, the mechanism remains unclear,[@b39-tacg-7-015],[@b57-tacg-7-015] and this has prevented the identification of a therapeutic target.

Improved identification of high-risk individuals
------------------------------------------------

In the case of CAD, primary prevention strategies in healthy asymptomatic individuals are very important because the first clinical manifestation of the disease is often catastrophic (MI or sudden death). Two main prevention strategies can be defined: the population approach, based on public health policies that affect the whole population, such as smoking bans;[@b58-tacg-7-015] and the approach that targets high-risk individuals, based on implementing intensive preventive treatment in individuals at high risk of having the disease, based on their cardiovascular risk factor profile.[@b59-tacg-7-015] Two main screening strategies are usually undertaken to identify high-risk individuals, ie, opportunistic screening and high-risk screening. In opportunistic screening, evaluation of cardiovascular risk factors and estimation of CAD risk is carried out in all individuals who come into contact with the health care system for any reason. Risk functions are the most commonly used method for estimating individual risk of having a CAD event, usually for a 10-year period.[@b59-tacg-7-015]--[@b61-tacg-7-015] Risk functions are mathematical equations that estimate the probability of developing CAD/cardiovascular disease using information about cardiovascular risk factors that are strongly and independently related to CAD and can be evaluated by simple procedures in the laboratory or doctor's office.

Depending on their estimated risk, it is possible to categorize individuals into different risk categories (low, intermediate, high, and very high), and these categories are used to determine the intensity of preventive cardiovascular measures to be applied, which may range from lifestyle recommendations to prescription of drugs with various clinical objectives. Although risk functions can accurately predict the numbers of events that will occur in each risk category, many CAD events occur in individuals whose risk is too low to justify intensive treatment.[@b62-tacg-7-015] For this reason, considerable effort has been invested in improving the classification of these intermediate-risk individuals into more appropriate risk categories.

Several biomarkers, including genetic variants, have been analyzed as candidates for improving the predictive capacity of risks functions.[@b63-tacg-7-015] The main advantage of genetic variants is that they remain invariable throughout life, so it is possible to determine a person's genetic risk profile before the development of an adverse cardiovascular risk factor profile, which would allow primary prevention measures to be undertaken earlier in life.[@b2-tacg-7-015],[@b63-tacg-7-015] Another advantage is the lower cost and higher replicability of genotyping compared with other cardiovascular risk factors. Among the limitations, the small effect sizes of known variants are most notable, despite the highly statistically significant associations between these variants and CAD risk.

Several studies have evaluated the effects on the predictive capacity of classical risk functions when genetic factors are taken into account. While most of the studies have found that these genetic variants (usually expressed as a single variable corresponding to the number of risk alleles carried, known as a genetic risk score) are associated with risk of future CAD events, they have not been found to improve the ability to discriminate between those individuals at particular risk who will develop the disease, although they do improve the reclassification of individuals into more appropriate risk categories, especially those at intermediate risk ([Table 5](#t5-tacg-7-015){ref-type="table"}).

Pharmacogenomics
================

Pharmacogenomics is the study of the relationship between genetic variability and a patient's response to drug treatment, ie, the efficacy of the drug and/or its adverse effects.[@b64-tacg-7-015]--[@b68-tacg-7-015] Candidate gene and GWAS approaches have been used to identify genetic variants associated with variability in drug response, including several examples in the cardiovascular field,[@b69-tacg-7-015],[@b70-tacg-7-015] the majority of which have focused on statins, antiplatelet drugs, oral anticoagulants, or beta-blockers. The case of statins and the antiplatelet agent clopidogrel provide two interesting examples in this area.

Statins are widely prescribed to reduce plasma cholesterol levels and cardiovascular risk, and although the majority of patients show a 30%--50% reduction in LDL cholesterol, high interindividual variability is observed.[@b71-tacg-7-015] Several genetic variants in the *HMGCR*, *APOE*, *CETP*, and *CLMN* genes have been reported to be associated with this interindividual variability, but the results have been discordant.[@b69-tacg-7-015],[@b70-tacg-7-015] Similarly, a variant in the *KIF6* gene has been reported to modulate the effect of statins on clinical outcome,[@b72-tacg-7-015],[@b73-tacg-7-015] but recent studies have not corroborated this finding.[@b74-tacg-7-015],[@b75-tacg-7-015] Finally, more than one variant in the *SLCO1B1* gene is consistently associated with the risk of simvastatin-induced myopathy, with an odds ratio \>4.[@b69-tacg-7-015],[@b76-tacg-7-015]

Our second example concerns the prodrug clopidogrel, which is converted into an active metabolite that selectively and irreversibly binds to the P2Y12 receptor on the platelet membrane. Conversion is achieved by the hepatic cytochrome P450 system in a two-step oxidative process, and cytochrome P450 2C19 is involved in both of these steps. The response to treatment with clopidogrel varies markedly between individuals, and the causes of a poor response are not clearly understood, but have been suggested to be related to clinical, cellular, or genetic factors.[@b66-tacg-7-015],[@b77-tacg-7-015],[@b78-tacg-7-015] In March 2010, the US Food and Drug Administration added a "boxed warning" to the labeling of clopidogrel, including a reference to patients who do not effectively metabolize the drug and therefore may not receive the full benefits on the basis of their genetic characteristics.[@b79-tacg-7-015] Recently, the American College of Cardiology Foundation and the American Heart Association have published a consensus document addressing this US Food and Drug Administration warning,[@b80-tacg-7-015] stating that the role of genetic tests and the clinical implications and consequences of this testing remain to be determined. Moreover, three recent meta-analyses question the validity of this warning based on the fact that the reported associations are mainly driven by studies with small sample sizes;[@b78-tacg-7-015],[@b81-tacg-7-015],[@b82-tacg-7-015] thus, they concluded that current evidence does not support the use of individualized clopidogrel regimens guided by the *CYP2C19* genotype.

Conclusion
==========

In the past 7 years, GWAS have contributed substantially to our understanding of the genetic architecture of complex diseases, including CAD. To date, approximately 40 unique loci have been found to be robustly associated with disease risk in large samples from several populations, a much higher number than those identified by linkage and candidate gene association studies. However, these variants explain only a small proportion of the heritability of CAD.[@b40-tacg-7-015] Additional efforts to improve the analysis strategies, including new imputation and meta-analytic methods, analysis of gene-gene and gene-environment interactions, the integration of different omics, and use of sequencing technologies, are being performed.[@b83-tacg-7-015]--[@b85-tacg-7-015]

Although it is not yet clear if or how all of this information on the genetic architecture of CAD can be translated into clinical practice,[@b86-tacg-7-015] we already have some exciting examples of its potential utility. To identify new therapeutic targets, we must first make the difficult transition from the statistical associations reported in GWAS to the functional mechanisms behind these associations. Research on the use of genetic information to improve cardiovascular risk estimation in individuals at intermediate risk can be carried out as a second step or in parallel, and further studies to develop new ways to include this information in risk functions, to evaluate its cost-effectiveness, and to explore the ethical issues are also warranted.[@b87-tacg-7-015]--[@b89-tacg-7-015] Finally, although medicine is always a "personalized science and art", use of genetic information to identify the most effective and least harmful drug for each patient is also a goal of so-called genetic personalized medicine.
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###### 

Main results of different studies analyzing the heritability of several phenotypes associated with arteriosclerosis

  Phenotype                         Heritability       References
  --------------------------------- ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------
  CAD                                                  
   Acute myocardial infarction      0.56               Nora et al[@b89-tacg-7-015]
   Mortality from                   0.53--0.57 (men)   Zdravkovic et al,[@b90-tacg-7-015]
   CAD                              0.58 (women)       Wienke et al[@b91-tacg-7-015]
   Coronary artery calcification    0.42               Peyser et al[@b92-tacg-7-015]
  Atherosclerosis                                      
   Carotid artery atherosclerosis   0.21--0.64         Xiang et al,[@b93-tacg-7-015] Fox et al,[@b94-tacg-7-015] Swan et al,[@b95-tacg-7-015] North et al,[@b96-tacg-7-015] Hunt et al[@b97-tacg-7-015]

**Abbreviation:** CAD, coronary artery disease.

###### 

Comparison between candidate gene studies and GWAS

  ------------------------------------------------------------------------------------------------------------------------
  Feature                      Candidate gene studies         Genome-wide association studies
  ---------------------------- ------------------------------ ------------------------------------------------------------
  Hypothesis                   Need a priori hypothesis       Hypothesis-free

  Number of genetic variants   Limited (one to hundreds)      Large (hundreds of thousands to millions, with imputation)

  Sample size                  Limited (usually hundreds)     Large (hundreds to hundreds of thousands)

  Biases                       Selection bias\                Selection bias\
                               Confounding\                   Confounding\
                               Population stratification\     Population stratification (methods to control)
                               Publication bias               

  Limitations                  Sample size\                   Control for multiple testing\
                               Nonreplicability of results\   Phenotype definition\
                               Lack of thoroughness\          Based on common variants\
                               Low genetic coverage           Statistical versus functional association

  False positive rate          Large                          Low

  False negative rate          Low                            Large
  ------------------------------------------------------------------------------------------------------------------------

**Note:** Data summarized from many studies.[@b28-tacg-7-015],[@b98-tacg-7-015]--[@b104-tacg-7-015]

**Abbreviation:** GWAS, genome-wide association studies.

###### 

Summary of main findings of most recent meta-analysis of genome-wide association studies in coronary artery disease, showing the lead single nucleotide polymorphism of each locus, the closest gene, chromosomal location, risk allele and frequency, *P*-value, and effect size of the reported associations

  rsID         Gene located at or near loci   Chr   Risk/nonrisk allele (risk allele frequency)   Combined *P*-value   Combined OR
  ------------ ------------------------------ ----- --------------------------------------------- -------------------- -------------
  rs602633     *SORT1*                        1     C/A (0.77)                                    1.47 × 10^−25^       1.12
  rs17114036   *PPAP2B*                       1     A/G (0.91)                                    5.80 × 10^−12^       1.11
  rs4845625    *IL6R*                         1     T/C (0.47)                                    3.64 × 10^−10^       1.09
  rs67258870   *WDR12*                        2     C/T (0.11)                                    1.16 × 10^−15^       1.12
  rs515135     *APOB*                         2     G/A (0.83)                                    2.56 × 10^−10^       1.03
  rs2252641    *ZEB2-ACO74093*                2     G/A (0.46)                                    5.30 × 10^−8^        1.06
  rs1561198    *VAMP5-VAMP8-GGCX*             2     A/G (0.45)                                    1.22 × 10^−10^       1.07
  rs6544713    *ABCG5-ABCG8*                  2     T/C (0.30)                                    2.12 × 10^−9^        0.96
  rs9818870    *MRAS*                         3     T/C (0.14)                                    2.62 × 10^−9^        1.07
  rs7692387    *GUCY1A3*                      4     G/A (0.81)                                    2.65 × 10^−11^       1.13
  rs1878406    *EDNRA*                        4     T/C (0.15)                                    2.54 × 10^−8^        1.09
  rs273909     *SLC22A4-SLC22A5*              5     C/T (0.14)                                    9.62 × 10^−10^       1.11
  rs12190287   *TCF21*                        6     C/G (0.59)                                    4.94 × 10^−13^       1.07
  rs2048327    *SLC22A3-LPAL2-LPA*            6     G/A (0.35)                                    6.86 × 10^−11^       1.06
  rs9369640    *PHACTR1*                      6     A/C (0.65)                                    7.53 × 10^−22^       1.09
  rs10947789   *KCKN5*                        6     T/C (0.76)                                    9.81 × 10^−9^        1.01
  rs4252120    *PLG*                          6     T/C (0.73)                                    4.88 × 10^10^        1.07
  rs11556924   *ZC3HC1*                       7     C/T (0.65)                                    6.74 × 10^−17^       1.09
  rs2023938    *HDAC9*                        7     G/A (0.10)                                    4.94 × 10^−8^        1.13
  rs264        *LPL*                          8     G/A (0.86)                                    2.88 × 10^−9^        1.06
  rs2954029    *TRIB1*                        8     A/T (0.55)                                    4.75 × 10^−9^        1.05
  rs1333049    *CDKN2BAS1*                    9     C/G (0.47)                                    1.39 × 10^−52^       1.23
  rs3217992                                   9     A/G (0.38)                                    7.75 × 10^−57^       1.16
  rs579459     *ABO*                          9     C/T (0.21)                                    2.66 × 10^−8^        1.07
  rs12413409   *CYP17A1-CNNM2-NT5C2*          10    G/A (0.89)                                    6.26 × 10^−8^        1.10
  rs2505083    *KIAA1462*                     10    C/T (0.42)                                    1.35 × 10^−11^       1.06
  rs501120     *CXCL12*                       10    A/G (0.83)                                    1.79 × 10^−9^        1.07
  rs2047009                                   10    C/A (0.48)                                    1.59 × 10^−9^        1.05
  rs974819     *PDGFD*                        11    A/G (0.29)                                    3.55 × 10^−11^       1.07
  rs3184504    *SH2B3*                        12    T/C (0.40)                                    5.44 × 10^−11^       1.07
  rs4773144    *COL4A1-COL4A2*                13    G/A (0.42)                                    1.43 × 10^−11^       1.07
  rs9515203                                   13    T/C (0.74)                                    5.85 × 10^−12^       1.08
  rs9319428    *FLT1*                         13    A/G (0.32)                                    7.32 × 10^−11^       1.10
  rs2895811    *HHIPL1*                       14    C/T (0.43)                                    4.08 × 10^−10^       1.06
  rs7173743    *ADAMTS7*                      15    T/C (0.58)                                    6.74 × 10^−13^       1.07
  rs17514846   *FURIN-FES*                    15    A/C (0.44)                                    9.33 × 10^−11^       1.04
  rs12936587   *RAI1-PEMT-RASD1*              17    G/A (0.59)                                    1.24 × 10^−9^        1.06
  rs2281727    *SMG6*                         17    C/T (0.36)                                    7.83 × 10^−9^        1.05
  rs1122608    *LDLR*                         19    G/T (0.76)                                    6.33 × 10^−14^       1.10
  rs9982601    Gene desert (*KCNE2*)          21    T/C (0.13)                                    7.67 × 10^−17^       1.13

**Abbreviations:** Chr, chromosome; OR, odds ratio.

###### 

Summary of main findings of most recent meta-analyses of genome-wide association studies of cardiovascular risk factors, showing the lead single nucleotide polymorphism of each locus, the closest gene, chromosomal location, risk allele and frequency, and *P*-value of the reported associations

  rsID                       Loci                 Chr       Risk allele (Risk allele frequency)       Combined *P*-value                             Known effect on CAD   Reference
  -------------------------- -------------------- --------- ----------------------------------------- -------------------- ------------------------- --------------------- -------------------
  Obesity                                                                                                                                                                  
   rs2815752                 *NEGR1*              1         A (0.61)                                  1.61 × 10^−22^                                 No                    [@b50-tacg-7-015]
   rs543874                  *SEC16B*             1         G (0.19)                                  3.56 × 10^−23^                                 No                    [@b50-tacg-7-015]
   rs1514175                 *TNNI3K*             1         A (0.43)                                  8.16 × 10^−14^                                 No                    [@b50-tacg-7-015]
   rs1555543                 *PTBP2*              1         C (0.59)                                  3.68 × 10^−10^                                 No                    [@b50-tacg-7-015]
   rs984222                  *TBX15-WARS2*        1         G (0.64)                                  3.81 × 10^−14^                                 No                    [@b49-tacg-7-015]
   rs2867125                 *TMEM18*             2         C (0.83)                                  2.77 × 10^−49^                                 No                    [@b50-tacg-7-015]
   rs713586                  *RBJ*                2         C (0.47)                                  6.17 × 10^−22^                                 No                    [@b50-tacg-7-015]
   rs887912                  *FANCL*              2         T (0.29)                                  1.79 × 10^−12^                                 No                    [@b50-tacg-7-015]
   rs10195252                *GRB14*              2         T (0.60)                                  2.09 × 10^−24^                                 No                    [@b49-tacg-7-015]
   rs13078807                *LRP1B*              2         C (0.18)                                  1.35 × 10^−10^                                 No                    [@b50-tacg-7-015]
   rs9816226                 *ETV5*               3         T (0.82)                                  1.69 × 10^−18^                                 No                    [@b50-tacg-7-015]
   rs13078807                *CADM2*              3         G (0.20)                                  3.94 × 10^−11^                                 No                    [@b50-tacg-7-015]
   rs6795735                 *ADAMTS9*            3         C (0.60)                                  9.79 × 10^−14^                                 No                    [@b49-tacg-7-015]
   rs6784615                 *NISCH-STAB1*        3         T (0.94)                                  3.84 × 10^−10^                                 No                    [@b49-tacg-7-015]
   rs13107325                *SLC39A8*            4         T (0.07)                                  1.50 × 10^−13^                                 No                    [@b50-tacg-7-015]
   rs10938397                *GNPDA2*             4         G (0.43)                                  3.78 × 10^−31^                                 No                    [@b50-tacg-7-015]
   rs2112347                 *FLJ35779*           5         T (0.63)                                  2.17 × 10^−13^                                 No                    [@b50-tacg-7-015]
   rs4836133                 *ZNF608*             5         A (0.48)                                  1.97 × 10^−9^                                  No                    [@b50-tacg-7-015]
   rs681681                  *CPEB4*              5         A (0.34)                                  1.91 × 10^−9^                                  No                    [@b49-tacg-7-015]
   rs987237                  *TFAP2B*             6         G (0.18)                                  2.90 × 10^−20^                                 No                    [@b50-tacg-7-015]
   rs206936                  *NUDT3*              6         G (0.21)                                  3.02 × 10^−8^                                  No                    [@b50-tacg-7-015]
   rs9491696                 *RSPO3*              6         G (0.48)                                  1.84 × 10^−40^                                 No                    [@b49-tacg-7-015]
   rs6905288                 *VEGFA*              6         A (0.56)                                  5.88 × 10^−25^                                 No                    [@b49-tacg-7-015]
   rs1294421                 *LY86*               6         G (0.61)                                  1.75 × 10^−17^                                 No                    [@b49-tacg-7-015]
   rs1055144                 *NFE2L3*             7         T (0.21)                                  9.97 × 10^−18^                                 No                    [@b49-tacg-7-015]
   rs10968576                *LRRN6C*             9         G (0.31)                                  2.65 × 10^−13^                                 No                    [@b50-tacg-7-015]
   rs10767664                *BNF*                11        A (0.78)                                  4.69 × 10^−26^                                 No                    [@b50-tacg-7-015]
   rs3817334                 *MTCH2*              11        T (0.40)                                  1.59 × 10^−12^                                 No                    [@b50-tacg-7-015]
   rs4929949                 *RPL27A*             11        C (0.52)                                  2.80 × 10^−9^                                  No                    [@b50-tacg-7-015]
   rs7138803                 *FAIM2*              12        A (0.38)                                  1.82 × 10^−17^                                 No                    [@b50-tacg-7-015]
   rs718314                  *ITPR2-SSPN*         12        G (0.26)                                  1.14 × 10^−17^                                 No                    [@b50-tacg-7-015]
   rs1443512                 *HOXC13*             12        A (0.24)                                  6.38 × 10^−17^                                 No                    [@b49-tacg-7-015]
   rs4771122                 *MTIF3*              13        G (0.24)                                  9.48 × 10^−10^                                 No                    [@b50-tacg-7-015]
   rs10150332                *NRXN3*              14        C (0.21)                                  2.75 × 10^−11^                                 No                    [@b50-tacg-7-015]
   rs11847697                *PRKD1*              14        T (0.04)                                  5.76 × 10^−11^                                 No                    [@b50-tacg-7-015]
   rs2241423                 *MAP2K5*             15        G (0.78)                                  1.19 × 10^−18^                                 No                    [@b50-tacg-7-015]
   rs1558902                 *FTO*                16        A (0.42)                                  4.8 × 10^−120^                                 No                    [@b50-tacg-7-015]
   rs7359397                 *SH2B1*              16        T (0.40)                                  1.88 × 10^−20^                                 No                    [@b50-tacg-7-015]
   rs12444979                *GPRC5B*             16        C (0.87)                                  2.91 × 10^−21^                                 No                    [@b50-tacg-7-015]
   rs571312                  *MC4R*               18        A (0.24)                                  6.43 × 10^−42^                                 No                    [@b50-tacg-7-015]
   rs29941                   *KCTD15*             19        G (0.67)                                  3.01 × 10^−9^                                  No                    [@b50-tacg-7-015]
   rs2287019                 *QPCTL*              19        C (0.80)                                  1.88 × 10^−16^                                 No                    [@b50-tacg-7-015]
   rs3810291                 *TMEM160*            19        A (0.67)                                  1.64 × 10^−12^                                 No                    [@b50-tacg-7-015]
   rs4823006                 *ZNRF3-KREMEN1*      22        A (0.57)                                  1.10 × 10^−11^                                 No                    [@b49-tacg-7-015]
  Diabetes                                                                                                                                                                 
   rs340874                  *PROX1*              1         C (0.52)                                  6.6 × 10^−12^                                  No                    [@b47-tacg-7-015]
   rs560887                  *G6PC2*              2         C (0.70)                                  8.7 × 10^−218^                                 No                    [@b47-tacg-7-015]
   rs780094                  *GCKR*               2         C (0.62)                                  5.6 × 10^−38^                                  No                    [@b47-tacg-7-015]
   rs243021                  *BCL11A*             2         A (0.46)                                  2.9 × 10^−15^                                  No                    [@b52-tacg-7-015]
   rs7578326                 *IRS1*               2         A (0.64)                                  5.4 × 10^−20^                                  No                    [@b52-tacg-7-015]
   rs11708067                *ADCY5*              3         A (0.78)                                  7.1 × 10^−22^                                  No                    [@b47-tacg-7-015]
   rs11920090                *SLC2A2*             3         T (0.87)                                  8.1 × 10^−13^                                  No                    [@b47-tacg-7-015]
   rs4457053                 *ZBED3*              5         G (0.26)                                  2.8 × 10^−12^                                  No                    [@b52-tacg-7-015]
   rs4607517                 *GCK*                7         A (0.16)                                  6.5 × 10^−92^                                  No                    [@b47-tacg-7-015]
   rs2191349                 *DGKB-TMEM195*       7         T (0.52)                                  3.0 × 10^−44^                                  No                    [@b47-tacg-7-015]
   rs972283                  *KLF14*              7         G (0.55)                                  2.2 × 10^−10^                                  No                    [@b52-tacg-7-015]
   rs11558471                *SLC30A8*            8         A (0.68)                                  NA                                             No                    [@b47-tacg-7-015]
   rs896854                  *TP53INP1*           8         T (0.48)                                  9.9 × 10^−10^                                  No                    [@b52-tacg-7-015]
   rs7034200                 *GLIS3*              9         A (0.49)                                  1.0 × 10^−12^                                  No                    [@b47-tacg-7-015]
   rs13292136                *CHCHD9*             9         C (0.93)                                  2.8 × 10^−8^                                   No                    [@b52-tacg-7-015]
   rs10885122                *ADRA2A*             10        G (0.87)                                  2.9 × 10^−16^                                  No                    [@b47-tacg-7-015]
   rs4506565                 *TCF7L2*             10        T (0.31)                                  NA                                             No                    [@b47-tacg-7-015]
   rs10830963                *MTNR1B*             11        G (0.30)                                  5.8 × 10^−175^                                 No                    [@b47-tacg-7-015]
   rs7944584                 *MADD*               11        A (0.75)                                  2.0 × 10^−18^                                  No                    [@b47-tacg-7-015]
   rs174550                  *FADS1*              11        T (0.64)                                  1.7 × 10^−15^                                  No                    [@b47-tacg-7-015]
   rs11605924                *CRY2*               11        A (0.49)                                  1.0 × 10^−14^                                  No                    [@b47-tacg-7-015]
   rs231362                  *KCNQ1*              11        G (0.52)                                  2.8 × 10^−13^                                  No                    [@b52-tacg-7-015]
   rs1552224                 *CENTD2*             11        A (0.88)                                  1.4 × 10^−22^                                  No                    [@b52-tacg-7-015]
   rs1387153                 *MTNR1B*             11        T (0.28)                                  7.8 × 10^−15^                                  No                    [@b52-tacg-7-015]
   rs1531343                 *HMGA2*              12        C (0.10)                                  3.6 × 10^−9^                                   No                    [@b52-tacg-7-015]
   rs7957197                 *HNF1A*              12        T (0.85)                                  2.4 × 10^−8^                                   No                    [@b52-tacg-7-015]
   rs11634397                *ZFAND6*             15        G (0.60)                                  2.4 × 10^−9^                                   No                    [@b52-tacg-7-015]
   rs11071657                *C2CD4B*             15        A (0.63)                                  3.6 × 10^−8^                                   No                    [@b47-tacg-7-015]
   rs8042680                 *PRC1*               15        A (0.22)                                  2.4 × 10^−10^                                  No                    [@b52-tacg-7-015]
   rs5945326                 *DUSP9*              X         A (0.79)                                  3.0 × 10^−10^                                  No                    [@b52-tacg-7-015]
  Total cholesterol                                                                                                                                                        
   rs12027135                *LDLRAP1*            1         T (0.45)                                  4 × 10^−11^                                    Yes                   [@b51-tacg-7-015]
   rs7515577                 *EVI5*               1         A (0.21)                                  3 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs2642442                 *MOSC1*              1         T (0.32)                                  6 × 10^−13^                                    No                    [@b51-tacg-7-015]
   rs514230                  *IRF2BP2*            1         T (0.48)                                  5 × 10^−14^                                    No                    [@b51-tacg-7-015]
   rs7570971                 *RAB3GAP1*           2         C (0.34)                                  2 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs2290159                 *RAF1*               3         G (0.22)                                  4 × 10^−9^                                     No                    [@b51-tacg-7-015]
   rs12916                   *HMGCR*              5         T (0.39)                                  9 × 10^−47^                                    No                    [@b51-tacg-7-015]
   rs6882076                 *TIMD4*              5         C (0.35)                                  7 × 10^−28^                                    No                    [@b51-tacg-7-015]
   rs3177928                 *HLA*                6         G (0.16)                                  4 × 10^−19^                                    No                    [@b51-tacg-7-015]
   rs2814982                 *C6orf106*           6         C (0.11)                                  5 × 10^−11^                                    No                    [@b51-tacg-7-015]
   rs9488822                 *FRK*                6         A (0.35)                                  2 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs12670798                *DNAH11*             7         T (0.23)                                  9 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs2072183                 *NPC1L1*             7         G (0.25)                                  3 × 10^−11^                                    No                    [@b51-tacg-7-015]
   rs2081687                 *CYP7A1*             8         C (0.35)                                  2 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs2737229                 *TRPS1*              8         A (0.30)                                  2 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs2255141                 *GPAM*               10        G (0.30)                                  2 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs10128711                *SPTY2D1*            11        C (0.28)                                  3 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs7941030                 *UBASH3B*            11        C (0.38)                                  2 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs11065987                *BRAP*               12        A (0.42)                                  7 × 10^−12^                                    No                    [@b51-tacg-7-015]
   rs1169288                 *HNF1A*              12        A (0.33)                                  1 × 10^−14^                                    No                    [@b51-tacg-7-015]
   rs2000999                 *HPR*                16        G (0.20)                                  3 × 10^−24^                                    No                    [@b51-tacg-7-015]
   rs4420638                 *CILP2*              19        T (0.07)                                  3 × 10^−38^                                    No                    [@b51-tacg-7-015]
   rs492602                  *FLJ36070*           19        A (0.49)                                  2 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs2277862                 *ERGIC3*             20        C (0.15)                                  4 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs2902940                 *MAFB*               20        A (0.29)                                  6 × 10^−11^                                    No                    [@b51-tacg-7-015]
  Triglycerides                                                                                                                                                            
   rs2131925                 *ANGPTL3*            1         T (0.32)                                  9 × 10^−43^                                    No                    [@b51-tacg-7-015]
   rs1042034                 *APOB*               2         T (0.22)                                  1 × 10^−45^                                    Yes                   [@b51-tacg-7-015]
   rs1260326                 *GCKR*               2         C (0.41)                                  6 × 10^−133^                                   No                    [@b51-tacg-7-015]
   rs10195252                *COBLL1*             2         T (0.40)                                  2 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs645040                  *MSL2L1*             3         T (0.22)                                  3 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs442177                  *KLHL8*              4         T (0.41)                                  9 × 10^−12^                                    No                    [@b51-tacg-7-015]
   rs9686661                 *MAP3K1*             5         C (0.20)                                  1 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs2247056                 *HLA*                6         C (0.25)                                  2 × 10^−15^                                    No                    [@b51-tacg-7-015]
   rs13238203                *TYW1B*              7         C (0.04)                                  1 × 10^−9^                                     No                    [@b51-tacg-7-015]
   rs17145738                *MLXIPL*             7         C (0.12)                                  6 × 10^−58^                                    No                    [@b51-tacg-7-015]
   rs11776767                *PINX1*              8         G (0.37)                                  1 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs1495741                 *NAT2*               8         A (0.22)                                  5 × 10^−14^                                    No                    [@b51-tacg-7-015]
   rs12678919                *LPL*                8         A (0.12)                                  2 × 10^−115^                                   Yes                   [@b51-tacg-7-015]
   rs2954029                 *TRIB1*              8         A (0.47)                                  3 × 10^−55^                                    Yes                   [@b51-tacg-7-015]
   rs10761731                *JMJD1C*             10        A (0.43)                                  3 × 10^−12^                                    No                    [@b51-tacg-7-015]
   rs2068888                 *CYP26A1*            10        G (0.46)                                  2 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs174546                  *FADS1--2--3*        11        C (0.34)                                  5 × 10^−24^                                    No                    [@b51-tacg-7-015]
   rs964184                  *APOA1*              11        C (0.13)                                  7 × 10^−240^                                   Yes                   [@b51-tacg-7-015]
   rs11613352                *LRP1*               12        C (0.23)                                  4 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs2412710                 *CAPN3*              15        G (0.02)                                  2 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs2929282                 *FRMD5*              15        A (0.05)                                  2 × 10^−11^                                    No                    [@b51-tacg-7-015]
   rs11649653                *CTF1*               16        C (0.40)                                  3 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs439401                  *APOE*               19        C (0.36)                                  1 × 10^−30^                                    No                    [@b51-tacg-7-015]
   rs5756931                 *PLA2G6*             22        T (0.40)                                  4 × 10^−8^                                     No                    [@b51-tacg-7-015]
  Low-density lipoprotein                                                                                                                                                  
   rs2479409                 *PCSK9*              1         A (0.23)                                  2 × 10^−28^                                    No                    [@b51-tacg-7-015]
   rs629301                  *SORT1*              1         T (0.22)                                  1 × 10^−170^                                   Yes                   [@b51-tacg-7-015]
   rs1367117                 *APOB*               2         G (0.30)                                  4 × 10^−114^                                   Yes                   [@b51-tacg-7-015]
   rs499376                  *ABCG5/8*            2         T (0.30)                                  2 × 10^−47^                                    Yes                   [@b51-tacg-7-015]
   rs3757354                 *MYLIP*              6         C (0.22)                                  1 × 10^−11^                                    No                    [@b51-tacg-7-015]
   rs1800562                 *HFE*                6         G (0.06)                                  6 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs1564348                 *LPA*                6         T (0.17)                                  2 × 10^−17^                                    Yes                   [@b51-tacg-7-015]
   rs11136341                *PLEC1*              8         A (0.40)                                  4 × 10^−13^                                    No                    [@b51-tacg-7-015]
   rs9411489                 *ABO*                9         C (0.20)                                  6 × 10^−13^                                    Yes                   [@b51-tacg-7-015]
   rs11220462                *ST3GAL4*            11        G (0.14)                                  1 × 10^−15^                                    No                    [@b51-tacg-7-015]
   rs8017377                 *NYNRIN*             14        G (0.47)                                  5 × 10^−11^                                    No                    [@b51-tacg-7-015]
   rs7206971                 *OSBPL7*             17        G (0.49)                                  2 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs6511720                 *LDLR*               19        G (0.11)                                  4 × 10^−117^                                   Yes                   [@b51-tacg-7-015]
   rs4420638                 *APOE*               19        A (0.17)                                  9 × 10^−147^                                   No                    [@b51-tacg-7-015]
   rs6029526                 *TOP1*               20        T (0.47)                                  4 × 10^−19^                                    No                    [@b51-tacg-7-015]
  High-density lipoprotein                                                                                                                                                 
   rs4660293                 *PABPC4*             1         A (0.23)                                  4 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs1689800                 *ZNF648*             1         A (0.35)                                  3 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs4846914                 *GALNT2*             1         A (0.40)                                  4 × 10^−21^                                    No                    [@b51-tacg-7-015]
   rs2972146                 *IRS1*               2         T (0.37)                                  3 × 10^−9^                                     No                    [@b51-tacg-7-015]
   rs12328675                *COBLL1*             2         T (0.13)                                  3 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs13107325                *SLC39A8*            4         C (0.07)                                  7 × 10^−11^                                    No                    [@b51-tacg-7-015]
   rs6450176                 *ARL15*              5         G (0.26)                                  5 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs2814944                 *C6orf106*           6         G (0.16)                                  4 × 10^−9^                                     No                    [@b51-tacg-7-015]
   rs605066                  *CITED2*             6         T (0.42)                                  3 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs1084651                 *LPA*                6         G (0.16)                                  3 × 10^−8^                                     Yes                   [@b51-tacg-7-015]
   rs2293889                 *TRPS1*              8         G (0.41)                                  6 × 10^−11^                                    No                    [@b51-tacg-7-015]
   rs4731702                 *KLF14*              7         C (0.48)                                  1 × 10^−15^                                    No                    [@b51-tacg-7-015]
   rs9987289                 *PPP1R3B*            8         G (0.09)                                  6 × 10^−25^                                    No                    [@b51-tacg-7-015]
   rs581080                  *TTC39B*             9         C (0.18)                                  3 × 10^−12^                                    No                    [@b51-tacg-7-015]
   rs1883025                 *ABCA1*              9         C (0.25)                                  2 × 10^−33^                                    No                    [@b51-tacg-7-015]
   rs2923084                 *AMPD3*              11        A (0.17)                                  5 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs3136441                 *LRP4*               11        T (0.15)                                  3 × 10^−18^                                    No                    [@b51-tacg-7-015]
   rs7134594                 *PDE3A*              12        C (0.42)                                  4 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs7134594                 *MVK*                12        T (0.47)                                  7 × 10^−15^                                    No                    [@b51-tacg-7-015]
   rs4759375                 *SBNO1*              12        C (0.06)                                  7 × 10^−9^                                     No                    [@b51-tacg-7-015]
   rs4765127                 *ZNF664*             12        G (0.34)                                  3 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs838880                  *SCARB1*             12        T (0.31)                                  3 × 10^−14^                                    No                    [@b51-tacg-7-015]
   rs1532085                 *LIPC*               15        G (0.39)                                  3 × 10^−96^                                    No                    [@b51-tacg-7-015]
   rs2652834                 *LACTB*              15        G (0.20)                                  9 × 10^−9^                                     No                    [@b51-tacg-7-015]
   rs3764261                 *CETP*               16        C (0.32)                                  7 × 10^−380^                                   No                    [@b51-tacg-7-015]
   rs16942887                *LCAT*               16        G (0.12)                                  8 × 10^−33^                                    No                    [@b51-tacg-7-015]
   rs2925979                 *CMIP*               16        C (0.30)                                  2 × 10^−11^                                    No                    [@b51-tacg-7-015]
   rs11869286                *STARD3*             17        C (0.34)                                  1 × 10^−13^                                    No                    [@b51-tacg-7-015]
   rs4148008                 *ABCA8*              17        C (0.32)                                  2 × 10^−10^                                    No                    [@b51-tacg-7-015]
   rs4129767                 *PGS1*               17        A (0.49)                                  8 × 10^−9^                                     No                    [@b51-tacg-7-015]
   rs7241918                 *LIPG*               18        T (0.17)                                  3 × 10^−49^                                    No                    [@b51-tacg-7-015]
   rs12967135                *MC4R*               18        G (0.23)                                  7 × 10^−9^                                     No                    [@b51-tacg-7-015]
   rs7255436                 *ANGPTL4*            19        A (0.47)                                  3 × 10^−8^                                     No                    [@b51-tacg-7-015]
   rs737337                  *LOC55908*           19        T (0.08)                                  3 × 10^−9^                                     No                    [@b51-tacg-7-015]
   rs386000                  *LILRA3*             19        G (0.20)                                  4 × 10^−19^                                    No                    [@b51-tacg-7-015]
   rs1800961                 *HNF4A*              20        C (0.03)                                  1 × 10^−15^                                    No                    [@b51-tacg-7-015]
   rs6065906                 *PLTP*               20        T (0.18)                                  2 × 10^−22^                                    No                    [@b51-tacg-7-015]
   rs181362                  *UBE2L3*             22        C (0.20)                                  1 × 10^−8^                                     No                    [@b51-tacg-7-015]
  **rsID**                   **Loci**             **Chr**   **Risk allele (Risk allele frequency)**   ***P*-value**        **Known effect On CAD**   **Reference**         
  **SBP**                    **DBP**                                                                                                                                       
                                                                                                                                                                           
  Blood pressure                                                                                                                                                           
   rs2932538                 *MOV10*              1         G (0.75)                                  1.2 × 10^−9^         9.9 × 10^−10^             No                    48
   rs17367504                *MTHFR-NPPB*         1         G (0.15)                                  8.7 × 10^−22^        3.5 × 10^−19^             No                    48
   rs13002573                *FIGN*               2         G (0.20)                                  3.25 × 10^−7^        4.02 × 10^−2^             No                    53
   rs1446468                 *FIGN*               2         T (0.53)                                  1.82 × 10^−12^       6.88 × 10^−9^             No                    53
   rs319690                  *MAP4*               3         T (0.51)                                  4.74 × 10^−8^        1.84 × 10^−8^             No                    53
   rs13082711                *SLC4A7*             3         T (0.78)                                  1.5 × 10^−6^         3.8 × 10^−9^              No                    48
   rs419076                  *MECOM*              3         T (0.47)                                  1.80 × 10^−13^       2.1 × 10^−12^             No                    48
   rs3774372                 *ULK4*               3         T (0.83)                                  0.39                 9.0 × 10^−14^             No                    48
   rs871606                  *CHIC2*              4         T (0.86)                                  3.04 × 10^−4^        8.85 × 10^−1^             No                    53
   rs13107325                *SLC39A8*            4         T (0.05)                                  3.3 × 10^−14^        2.3 × 10^−17^             No                    48
   rs13139571                *GUCY1A3-GUCY1B3*    4         C (0.76)                                  1.2 × 10^−6^         2.2 × 10^−10^             Yes                   48
   rs1458038                 *FGF5*               4         T (0.29)                                  1.5 × 10^−23^        8.5 × 10^−25^             No                    48
   rs1173771                 *NPR3-C5orf23*       5         G (0.60)                                  1.8 × 10^−16^        9.1 × 10^−12^             No                    48
   rs11953630                *EBF1*               5         T (0.37)                                  3.0 × 10^−11^        3.8 × 10^−13^             No                    48
   rs1799945                 *HFE*                6         G (0.14)                                  7.7 × 10^−12^        1.5 × 10^−15^             No                    48
   rs805303                  *BAT2-BAT5*          6         G (0.61)                                  1.5 × 10^−11^        4.4 × 10^−10^             No                    48
   rs17477177                *PIK3CG*             7         T (0.72)                                  5.67 × 10^−11^       1.40 × 10^−1^             No                    53
   rs2071518                 *NOV*                8         T (0.17)                                  2.08 × 10^−2^        3.89 × 10^−3^             No                    53
   rs2782980                 *ADRB1*              10        T (0.20)                                  7.66 × 10^−7^        9.60 × 10^−8^             No                    53
   rs4373814                 *CACNB2*             10        G (0.55)                                  4.8 × 10^−11^        4.4 × 10^−10^             No                    48
   rs932764                  *PLCE1*              10        G (0.44)                                  7.1 × 10^−16^        8.1 × 10^−7^              No                    48
   rs1813353                 *CACNB2*             10        T (0.68)                                  2.6 × 10^−12^        2.3 × 10^−15^             No                    48
   rs4590817                 *C10orf107*          10        G (0.84)                                  4.0 × 10^−12^        1.3 × 10^−12^             No                    48
   rs11191548                *CYP17A1-NT5C2*      10        T (0.91)                                  6.9 × 10^−26^        9.4 × 10^−13^             Yes                   48
   rs11222084                *ADAMTS8*            11        T (0.38)                                  4.00 × 10^−4^        3.44 × 10^−2^             No                    53
   rs7129220                 *ADM*                11        G (0.89)                                  3.0 × 10^−12^        6.4 × 10^−8^              No                    48
   rs633185                  *FLJ32810-TMEM133*   11        G (0.28)                                  1.2 × 10^−17^        2.0 × 10^−15^             No                    48
   rs381815                  *PLEKHA7*            11        T (0.26)                                  5.3 × 10^−11^        5.3 × 10^−10^             No                    48
   rs17249754                *ATP2B1*             12        G (0.84)                                  1.8 × 10^−18^        1.2 × 10^−14^             No                    48
   rs3184504                 *SH2B3*              12        T (0.47)                                  3.8 × 10^−18^        3.6 × 10^−25^             Yes                   48
   rs10850411                *TBX5-TBX3*          12        T (0.70)                                  5.4 × 10^−8^         5.4 × 10^−10^             No                    48
   rs2521501                 *FURIN-FES*          15        T (0.31)                                  5.2 × 10^−19^        1.9 × 10^−15^             Yes                   48
   rs1378942                 *CYP1A1-ULK3*        15        C (0.35)                                  5.7 × 10^−23^        2.7 × 10^−26^             No                    48
   rs17608766                *GOSR2*              17        T (0.86)                                  1.1 × 10^−10^        0.017                     No                    48
   rs12940887                *ZNF652*             17        T (0.38)                                  1.8 × 10^−10^        2.3 × 10^−14^             No                    48
   rs1327235                 *JAG1*               20        G (0.46)                                  1.9 × 10^−8^         1.4 × 10^−15^             No                    48
   rs6015450                 *GNAS-EDN3*          20        G (0.12)                                  3.9 × 10^−23^        5.6 × 10^−23^             No                    48

**Abbreviations:** Chr, chromosome; CAD, coronary artery disease; SBP, systolic blood pressure; DBP, diastolic blood pressure.

###### 

Main characteristics and results of studies assessing improvement of predictive capacity of classical cardiovascular risk functions after inclusion of genetic information

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                   Population                                                  Clinical outcome                   Genetic variants                       Other covariates   Results                                                                                                                                                                                                
  ---------------------------------------- ----------------------------------------------------------- ---------------------------------- -------------------------------------- ------------------ --------- --------------------------------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------- -------------------------------------------------
  Case-control                                                                                                                                                                                                                                                                                                                                                                                             

   Davies et al[@b105-tacg-7-015]          OHGS3,323Ca/2,319 Co\                                       CAD                                One SNP(9p21)\                         Yes                No        NR                                                                                ΔAUC 0.003\                                             --                                                 --
                                           WTCC: 1,926 Ca/2,938 Co                                                                        12 SNPs (related and unrelated CVRF)                                                                                                                  ΔAUC 0.008[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                                       

   Anderson et al[@b106-tacg-7-015]        Patients undergoing coronary angiography: 1,086 Ca/482 Co   CAD                                5 SNPs (related and unrelated CVRF)    Yes                Yes       OR 1.24[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                 ΔAUC 0.008                                              16.0%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}    28.3%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}

   Qi et al[@b107-tacg-7-015]              Hispanic: 1,989 Ca/2,096 Co                                 Ml                                 3 SNPs (related and unrelated CVFR)    Yes                No        OR 1.18[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                 ΔAUC 0.010[‡](#tfn6-tacg-7-015){ref-type="table-fn"}    --                                                 --

   Qi et al[@b108-tacg-7-015]              Type II DM patients: 1,076\                                 CAD                                5 SNPs (related and unrelated CVRF)    Yes                No        OR 1.19[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                                                                         --                                                 --
                                           Ca/1,430 Co                                                                                                                                                                                                                                                                                                                                                     

   Lv et al[@b105-tacg-7-015]              Chinese Han population: 1,007 Ca/889 Co                     CAD                                8 SNPs (related and unrelated CVRF)    Yes                No        OR 1.28[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                 ΔAUC 0.022[‡](#tfn6-tacg-7-015){ref-type="table-fn"}    --                                                 --

   Patel et al[@b110-tacg-7-015]           US population: 1,338 Ca/1,649 Co (\>70 years)               Ml \<70 years                      11 SNPs                                Yes                Yes       OR 1.12[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                 ΔAUC 0.012[‡](#tfn6-tacg-7-015){ref-type="table-fn"}    --                                                 --

  Case-cohort                                                                                                                                                                                                                                                                                                                                                                                              

   Hughes et al[@b111-tacg-7-015]          Middle-aged men, European general population\               CAD                                11 SNPs + two haplotypes\              Yes\               No\       NR\                                                                               ΔAUC 0.009\                                             7.5%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\    6.3%\
                                           632 Ca/1,361 subcohort                                                                         11 SNPs + 4 SNPs (unrelated CVRF)      Yes                No        NR                                                                                ΔAUC 0.011[‡](#tfn6-tacg-7-015){ref-type="table-fn"}    6.5%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}     5.1%

   Vaarhorst et al[@b112-tacg-7-015]       European general population 742 Ca/2,22l subcohort          12.1 years follow-up, CAD          29 SNPs (unrelated CVRF)               Yes                No        HR 1.12[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                                                                         2.8%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}     NR

  Cohort                                                                                                                                                                                                                                                                                                                                                                                                   

   Morrison et al[@b113-tacg-7-015]        ARIC, US general population 13,907                          13 years follow-up, 1,452 CAD      10 SNPs -- White population\           Yes                No        HR 1.10[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\                                ΔAUC 0.002\                                             NR                                                 NR
                                                                                                                                          11 SNPs -- Black population                                         HR 1.20[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                 ΔAUC 0.011[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                                       

   Kathiresan et al[@b114-tacg-7-015]      Malmö, European general population, 4,232                   10.6 years follow-up, 238 CVD      9 SNPs, lipid-related                  Yes                No        HR 1.15[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                 ΔAUC 0.003                                              --                                                 --

   Talmud et al[@b115-tacg-7-015]          NPHS-II, UK middle-aged men, 2,742                          15 years follow-up, 270 CAD        1 SNP(9p21)                            Yes                Yes       AA versus AG 1.38[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\                      ΔAUC 0.02                                               13.8%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}    NR
                                                                                                                                                                                                              AA versus GG 1.57[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                                                                                                                  

   Brautbar et al[@b116-tacg-7-015]        ARIC, US general population (Whites), 9,998                 14.6 years follow-up, 1,349 CAD    1 SNP(9p21)                            Yes                No        HR 1.20[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                 ΔAUC 0.004[‡](#tfn6-tacg-7-015){ref-type="table-fn"}    0.8%                                               6.2[‡](#tfn6-tacg-7-015){ref-type="table-fn"}

   Paynter et al[@b117-tacg-7-015]         WGHS, US middle-aged\                                       10.2 years follow-up, 1,349 CVD    1 SNP(9p21)                            Yes                Yes       AA versus AG 1.25[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\                      ΔAUC 0.002                                              Framingham, 2.7%\                                  NR
                                           White women, 22,192                                                                                                                                                AA versus GG 1.32[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                                                               Reynolds, 0.2%                                     

   Paynter et al[@b118-tacg-7-015]         WGHS, US White women, 19,313                                12.3 years follow-up, 777 CVD      101 SNPs\                              Yes                Yes       HR 1.00\                                                                          ΔAUC 0.000\                                             0.5%\                                              NR
                                                                                                                                          12 SNPs (related and unrelated CVRF)                                HR 1.04                                                                           ΔAUC 0.001                                              0.5%                                               

   Ripatti et al[@b119-tacg-7-015]         General European population, 30,725                         10.7 years follow-up, 1,264 CHD    13 SNPs (related and unrelated CVRF)   Yes                Yes       HR 1.66(Q5 versus Q1)[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                   ΔAUC 0.001                                              2.2%                                               9.7%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}

   Shiffman et al[@b120-tacg-7-015]        CHS, US old population (\>65 years), 4,284                  12.6 years follow-up, Ml           1 SNP(9p2l)\                           Yes                No        HR 1.22 (White men)[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\                    ΔAUC 0.005\                                             2.1%\                                              
                                                                                                                                          1 SNP(KIF6719 Arg) carriers                                         HR 1.16 (White women)[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\                  ΔAUC 0.002\                                             −1.8%\                                             
                                                                                                                                                                                                              HR NR (Black men)HR 1.42 (White men)[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\   ΔAUC 0.034\                                             18.2%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\   
                                                                                                                                                                                                              HR 1.05 (White women)                                                             ΔAUC 0.015[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\   2.7%\                                              
                                                                                                                                                                                                                                                                                                ΔAUC −0.001                                             0.7%                                               

   Thanassoulis et al[@b121-tacg-7-015]    Framingham, US general population, 3,014                    11 years follow-up, 182 hard CHD   13 SNPs (related and unrelated CVRF)   Yes                Yes       HR 1.07[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                 ΔAUC 0.002                                              19.0%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}    NR

   Lluis-Ganella et al[@b122-tacg-7-015]   General population,\                                        11.9 years follow-up, 536 CHD      8 SNPs (unrelated CVRF)                Yes                Yes       HR 1.13[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                 ΔAUC No                                                 6.4%                                               17.4%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}
                                           Framingham 3,537 + REGICOR 2,351                                                                                                                                                                                                                                                                                                                                

   Gransbo et al[@b123-tacg-7-015]         Malmö, 24,777                                               11.7 years follow-up, 2,668 CVD    9p21 variant                           Yes                No        HR 1.17[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                 ΔAUC 0.001                                              1.2%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}     --

   Isaacs et al[@b124-tacg-7-015]          Erasmus Family study 2,269 + Rotterdam Study 8,130          9.5 years follow-up, 924 CHD       Lipid-related GRS                      Yes                No        GRS~TC~ HR 1.09[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\                        ΔAUC 0.000                                              --                                                 --
                                                                                                                                                                                                              GRS~LDL~ HR 1.08[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\                                                                                                                                  
                                                                                                                                                                                                              GRS~HDL~ HR 0.99\                                                                                                                                                                            
                                                                                                                                                                                                              GRS~TG~ HR 1.04                                                                                                                                                                              

   Ganna et al[@b125-tacg-7-015]           6 Swedish cohorts, 10,612                                   781 CHD                            GRS~global~, 395\                      Yes                No        HR 1.54[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\                                ΔAUC 0.002\                                             4.2%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}\    --
                                                                                                                                          GRS~CHD~, 46                                                        HR 1.52[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                 ΔAUC 0.004[‡](#tfn6-tacg-7-015){ref-type="table-fn"}    4.9%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}     

  Tikkanen et al[@b126-tacg-7-015]         4 Finnish cohorts, 24,124                                   12 years follow-up, 1,093 CHD      28 SNPs (related and unrelated CVRF)   Yes                Yes       HR 1.27[‡](#tfn6-tacg-7-015){ref-type="table-fn"}                                 ΔAUC 0.003[‡](#tfn6-tacg-7-015){ref-type="table-fn"}    5.0%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}     27.0%[‡](#tfn6-tacg-7-015){ref-type="table-fn"}
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

*P*-value\<0.05.

**Abbreviations:** ARIC, Atherosclerosis Risk in Communities study; CAD, coronary artery disease; Ml, myocardial infarction; CVD, cardiovascular disease; OHGS, Ottawa Heart Genomics Study; WTCCC, Wellcome Trust Case Control Consortium; Ca, Cases; Co, Controls; DM, diabetes mellitus; NPHS-11: Northwick Park Heart Study 11; WGHS, Women Genome Health Study; CHS, Cardiac Health Study; REGICOR, Registre Gironi del Cor (Girona Heart Registry); OR, odds ratio; HR, hazard ratio; NR, not reported; AUC, area under the receiver operating curve; NRI, Net Reclassification Index; CVRF, cardiovascular risk factors; GRS, genetic risk score; SNP, single nucleotide polymorphism.
